GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and ...

Tuberculosis is the world's leading infectious cause of death, killing more than one million people each year. When the ...

LONDON, UK I June 12, 2025 I GSK plc (LSE/NYSE: GSK) announced today that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

Scientists developed nanoparticles that respond to warmth inside tumors to boost ultrasound clarity, offering a safer and ...

† Department of Chemistry, Infection Innovative Medicines Unit, AstraZeneca-US, 53 Gatehouse Drive, Waltham, Massachusetts 02451, United States ‡ Department of Biosciences, Infection Innovative ...